My life & career
Gene editing already has narrow approved uses; broader benefits need safety, affordability and access.
THE YOTTABIT ERA / WHEN BREAKTHROUGHS COLLIDE
What if gene editing could become as precise as an address?
Imagine a treatment that targets the genetic instructions behind a disease rather than repeatedly managing what the disease causes.
HERE'S WHY THIS IS SUCH A BIG DEAL
For some conditions, healthcare may have opportunities to address underlying biology, not just the symptoms.
THE STORY IN PLAIN ENGLISH
Imagine being able to identify a mistake in the genetic instructions that contribute to a disease, and then develop a treatment aimed at that specific problem. Scientists have already shown that editing genes can help treat certain conditions, while artificial intelligence can assist in choosing what to study and checking possible effects. That opens an extraordinary door: medicine that sometimes addresses a cause rather than treating symptoms again and again. It does not mean genes can be edited as easily as a sentence in a document. Getting treatments into the right cells safely, understanding unintended effects and making care affordable remain difficult challenges.
THE YOTTABIT PERSPECTIVE
What does it mean to me?
Big change is fascinating. Its implications are what matter.
My business
Clinical and manufacturing pathways are as important as clever targeting software.
My industry
Healthcare systems, drug developers and insurers face new treatment and reimbursement questions.
FROM JIM CARROLL’S WORK
Jim’s healthcare work focuses on the shift from reactive care to targeted medical intervention.
Meet the futurist behind YottaBit ↗WHAT COULD I DO MONDAY MORNING?
Identify one condition where stronger targeting could matter—and the clinical evidence needed.
CURIOUS ABOUT THE SCIENCE?The story is exciting.
The story is exciting.
The evidence still matters.
Here's what researchers have demonstrated, what's still ahead, and where to check the source. It should deepen the story—not get in the way of understanding it.
Behind the breakthrough THE EVIDENCE +
What's happening today: First CRISPR-based FDA approval in 2023.
The next challenge: Safe delivery, clinical evidence, affordability and ethical safeguards remain major obstacles.
How the technologies connect: Computational genomics + CRISPR + clinical manufacturing.
Explore the original research
US FDA — First FDA approvals of CRISPR-based treatment, 2023 ↗